These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24731696)

  • 1. The thorny problem of dyskinesias: dendritic spines, synaptic plasticity, and striatal dysfunction.
    Deutch AY
    Biol Psychiatry; 2014 May; 75(9):676-7. PubMed ID: 24731696
    [No Abstract]   [Full Text] [Related]  

  • 2. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Nishijima H; Arai A; Kimura T; Mori F; Yamada J; Migita K; Wakabayashi K; Baba M; Ueno S; Tomiyama M
    Neuropathology; 2013 Aug; 33(4):391-6. PubMed ID: 23241013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.
    Fieblinger T; Cenci MA
    Mov Disord; 2015 Apr; 30(4):484-93. PubMed ID: 25759263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa treatment and dendritic spine pathology.
    Nishijima H; Ueno T; Funamizu Y; Ueno S; Tomiyama M
    Mov Disord; 2018 Jul; 33(6):877-888. PubMed ID: 28880414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
    Nishijima H; Suzuki S; Kon T; Funamizu Y; Ueno T; Haga R; Suzuki C; Arai A; Kimura T; Suzuki C; Meguro R; Miki Y; Yamada J; Migita K; Ichinohe N; Ueno S; Baba M; Tomiyama M
    Mov Disord; 2014 Mar; 29(3):336-43. PubMed ID: 24573720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
    Belujon P; Lodge DJ; Grace AA
    Mov Disord; 2010 Aug; 25(11):1568-76. PubMed ID: 20623773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic plasticity may underlie l-DOPA induced dyskinesia.
    Borgkvist A; Lieberman OJ; Sulzer D
    Curr Opin Neurobiol; 2018 Feb; 48():71-78. PubMed ID: 29125979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
    Klietz M; Keber U; Carlsson T; Chiu WH; Höglinger GU; Weihe E; Schäfer MK; Depboylu C
    Neuroscience; 2016 Sep; 331():120-33. PubMed ID: 27320210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.
    Alberico SL; Kim YC; Lence T; Narayanan NS
    Neuroscience; 2017 Feb; 343():240-249. PubMed ID: 27956068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.
    Picconi B; De Leonibus E; Calabresi P
    J Neural Transm (Vienna); 2018 Aug; 125(8):1263-1271. PubMed ID: 29492662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease.
    Nishijima H; Ueno T; Ueno S; Mori F; Miki Y; Tomiyama M
    Neurosci Res; 2017 Feb; 115():54-58. PubMed ID: 27773835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
    Brotchie JM
    Adv Neurol; 1999; 80():71-85. PubMed ID: 10410705
    [No Abstract]   [Full Text] [Related]  

  • 18. Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Picconi B; Hernández LF; Obeso JA; Calabresi P
    Mov Disord; 2018 Jul; 33(6):867-876. PubMed ID: 29219207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.